Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Genetics Institute is a U.S. based biotechnology research and development company. The company developed drugs such as Neumega and Recombinate used in the prevention of severe reductions in the number of blood clotting cells. The company was founded in 1980 by Thomas Maniatis and Mark Ptashne, and started off by operating out of Ptashne’s home. Genetics Institute was acquired by Wyeth in 1992 and operates as part of Wyeth’s research division.

Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

SyStemix develops cellular and cell-based gene therapies for cancer, AIDS, and genetic diseases based on the use of isolated, expanded, and gene-modified hematopoietic stem cells. The company is based in Palo Alto, California. SyStemix, Inc. was acquired by Novartis AG. In February 1997, SyStemix completed a merger with Novartis Biotech Holding Corp., an indirect wholly owned subsidiary of Novartis, Inc. Novartis shuttered Systemix in 2000.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Kirin Brewery Co., Ltd. engages in the manufacture of alcoholic beverages. Its products include beer, sparkling liquor, chuhai, gin, and whiskey. The company was founded in 1901 and is headquartered in Tokyo, Japan.

Estabished in1950, Snow Brand Milk Products Co. Ltd. is a Japanese dairy company that manufactures cheese, butter, milk and other dairy products. They also manufacture fruit juices and frozen desserts and offers home milk delivery service. Snow Brand has several offices and factories around Japan.

Research Development Foundation is an American private company that operates as noncommercial research organizations.

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Nuvelo, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. The Company’s development pipeline includes alfimeprase, a direct-acting fibrinolytic in Phase II development for the treatment of thrombotic-related disorders, including acute ischemic stroke and catheter occlusion (CO); NU172, a direct thrombin inhibitor in Phase I development for use as a short-acting anticoagulant during medical or surgical procedures, and preclinical candidate NU206 for the treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. (Source: 10-K)

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Kirin Pharma Co. Ltd. manufactures and sells pharmaceutical products. Its products include Nesp, Regpara Tablets, Espo, Phosblock and Gran. The company was founded in 2007 and is headquartered in Tokyo, Japan

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

ES Cell International Pte Ltd. develops human embroyonic stem cell technologies for research and commercial applications. It develops an array of intellectual property in the fields of drug discovery, diagnostics, and therapeutics based on stem cell technology. The company was founded by Ariff Bongso, Robert Klupacs, Martin F. Pera, Reubinoff Benjamin and Alan Osborne Trounson in 2000 and is headquartered in Singapore.

Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.